Aspirin does not prevent recurrence after treatment for colorectal cancer liver metastases
· Medical Xpressby Julie Nybakk Kvaal, University of Oslo
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
Colorectal cancer is one of the most common cancers in Norway, which also has one of the highest incidence rates in the world.
Approximately 30% of patients with colorectal cancer develop liver metastases during the course of their disease. Once the disease has spread, it is much more difficult to treat than primary colorectal cancer confined to the bowel.
"Patients rarely die from the primary tumor itself. It is the metastatic disease that is usually life-threatening," says Sheraz Yaqub, professor at the University of Oslo and consultant hepatobiliary surgeon at Oslo University Hospital.
For many patients, surgery offers the best chance of a cure.
"But even when we remove the tumors surgically, the cancer returns in more than half of patients," says Yaqub.
Previous studies have suggested a protective effect of aspirin
Previous observational studies have suggested that aspirin use after colorectal cancer treatment may be associated with a lower risk of recurrence and improved survival.
More recent randomized trials have investigated whether aspirin can provide such benefits, particularly in patients with specific molecular alterations in their tumors.
Yaqub and his colleagues wanted to find out whether aspirin could have the same preventive effect in patients whose colorectal cancer had spread to the liver.
"We wanted to know whether we could prevent the cancer from returning by giving aspirin to these patients as well," Yaqub says.
The study has now been published in The Lancet Gastroenterology & Hepatology.
An inexpensive and widely available medicine
Aspirin has long been used to treat pain, fever and inflammation. Its potential to prevent cancer recurrence has therefore attracted considerable interest.
"Aspirin is inexpensive, widely available and has been used for more than a century. Its effects and side effects are well known, which made it an attractive candidate for preventing cancer recurrence," says Yaqub.
Could aspirin prevent recurrence after treatment for liver metastases?
The researchers conducted ASAC, a randomized, double-blind, placebo-controlled trial investigating whether aspirin could reduce the risk of recurrence after curative-intent treatment of colorectal cancer liver metastases.
A total of 466 patients were randomized at 14 hospitals in Norway, Sweden and Denmark. All had undergone treatment (surgery or local ablation) for colorectal cancer liver metastases.
The participants were randomly assigned to receive either aspirin 160 mg daily or an identical placebo for up to three years.
"For most patients, the cancer returns within the first two years after surgery. That is why we followed participants for three years," says Yaqub.
No reduction in recurrence with aspirin
The researchers found that aspirin did not reduce the risk of the cancer returning, compared with placebo. Patients who received aspirin also had a lower overall survival rate, but this finding should be interpreted with caution. Serious adverse events were more common in the aspirin group.
"We found no benefit from aspirin in preventing cancer recurrence in these patients. The finding of lower overall survival, together with a higher frequency of serious adverse events, also raises concerns," says Yaqub.
"Our results show that aspirin should not be routinely recommended to prevent recurrence after curative-intent treatment of colorectal cancer liver metastases," he adds.
Why randomized trials matter
In an earlier study, Yaqub and colleagues linked information from the Norwegian Cancer Registry and the Norwegian Prescription Database. That registry-based study suggested that patients with colorectal cancer who were taking aspirin lived longer than those who were not.
However, studies based on health registries cannot show with certainty whether a treatment was the reason for the difference.
"Registry studies can identify associations, but they cannot establish whether aspirin itself is responsible for improved survival. Randomized, placebo-controlled trials provide much stronger evidence about the effects of treatment," he explains.
Why might aspirin benefit some patients but not others?
The reasons are not yet clear, but differences in disease stage and tumor biology may play a role.
The ASAC trial was conducted alongside the Scandinavian ALASCCA trial. Both studies examined molecular changes in tumor tissue.
The ALASCCA study found that aspirin reduced recurrence in some patients with localized colorectal cancer whose tumors carried specific alterations in the PI3K signaling pathway. In contrast, the ASAC trial found no benefit for patients who had been treated for colorectal cancer that had spread to the liver, including those with the molecular alterations examined in the study.
"What works for one group of patients does not necessarily work for another. We cannot simply transfer results from patients with primary colorectal cancer to patients who have been treated for liver metastases," says Yaqub.
Do not stop taking aspirin without medical advice
The ASAC trial investigated the effect of starting aspirin after cancer treatment. Patients who were already taking aspirin were not eligible to take part.
The findings therefore do not mean that people who already take aspirin for other medical reasons should stop treatment.
"Patients who are already taking aspirin for cardiovascular disease or other medical indications should not stop treatment because of these findings. Any changes should be discussed with their treating physician," Yaqub says.
Publication details
Sheraz Yaqub et al., Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial, The Lancet Gastroenterology & Hepatology (2026). DOI: 10.1016/s2468-1253(26)00260-8
Journal information: The Lancet Gastroenterology & Hepatology
Key medical concepts
Clinical categories
OncologyGastroenterology Provided by University of Oslo Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Aspirin does not prevent recurrence after treatment for colorectal cancer liver metastases (2026, November 8) retrieved 8 November 2026 from https://medicalxpress.com/news/2026-11-aspirin-recurrence-treatment-colorectal-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.